Osamu Muto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Osamu Muto has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Chieko Takashima
Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan
1 shared publication- Daisuke Muraoka
Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan
1 shared publication Haruka Hayakawa
School of International Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
1 shared publicationHiroaki Ikeda
Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
1 shared publicationHirokazu Matsushita
Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan
1 shared publicationKazunari Akiyoshi
Department of Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
1 shared publication
Latest Publications
- Open Access
- 18 September 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-17
Low-frequency CD8+ T cells induced by SIGN-R1+ macrophage-targeted vaccine confer SARS-CoV-2 clearance in mice
Vaccine-induced T cells and neutralizing antibodies are essential for protection against SARS-CoV-2. Previously, we demonstrated that an antigen delivery system, pullulan nanogel (PNG), delivers vaccine antigen to lymph node medullary macrophages and thereby enhances the induction of specific CD8+ T cells. In this study, we revealed that medullary macrophage-selective delivery by PNG depends on its binding to a C-type lectin SIGN-R1. In a K18-hACE2 mouse model of SARS-CoV-2 infection, vaccination with a PNG-encapsulated receptor-binding domain of spike protein decreased the viral load and prolonged the survival in the CD8+ T cell- and B cell-dependent manners. T cell receptor repertoire analysis revealed that although the vaccine induced T cells at various frequencies, low-frequency specific T cells mainly promoted virus clearance. Thus, the induction of specific CD8+ T cells that respond quickly to viral infection, even at low frequencies, is important for vaccine efficacy and can be achieved by SIGN-R1+ medullary macrophage-targeted antigen delivery.
- 18 September 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-17
Open AccessLow-frequency CD8+ T cells induced by SIGN-R1+ macrophage-targeted vaccine confer SARS-CoV-2 clearance in mice
Vaccine-induced T cells and neutralizing antibodies are essential for protection against SARS-CoV-2. Previously, we demonstrated that an antigen delivery system, pullulan nanogel (PNG), delivers vaccine antigen to lymph node medullary macrophages and thereby enhances the induction of specific CD8+ T cells. In this study, we revealed that medullary macrophage-selective delivery by PNG depends on its binding to a C-type lectin SIGN-R1. In a K18-hACE2 mouse model of SARS-CoV-2 infection, vaccination with a PNG-encapsulated receptor-binding domain of spike protein decreased the viral load and prolonged the survival in the CD8+ T cell- and B cell-dependent manners. T cell receptor repertoire analysis revealed that although the vaccine induced T cells at various frequencies, low-frequency specific T cells mainly promoted virus clearance. Thus, the induction of specific CD8+ T cells that respond quickly to viral infection, even at low frequencies, is important for vaccine efficacy and can be achieved by SIGN-R1+ medullary macrophage-targeted antigen delivery.